Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Rituximab + Subasumstat|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Rituximab||Rituxan||IDEC-C2B8|MabThera||CD20 Antibody 21||Rituxan (rituximab) is a chimeric mononclonal antibody that binds to CD20 on B-cells, resulting in induction of complement-dependent and antibody-dependent cytotoxicity, and potentially leading to decreased B-cell tumor growth (PMID: 28983798). Rituxan (rituximab) is FDA approved for use as monotherapy or in combination with chemotherapy in CD20-positive B-cell non-Hodgkin lymphoma, in combination with fludarabine and cyclophosphamide in CD20-positive chronic lymphocytic leukemia, and in combination with chemotherapy in pediatric patients (6 month to 18 years of age) with treatment-naive, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia (B-AL) (FDA.gov).|
|Subasumstat||TAK981|TAK 981|TAK-981||Subasumstat (TAK-981) is a small molecule inhibitor of the SUMO-activating enzyme (SAE), which may lead to activation of anti-tumor immune response and inhibition of tumor growth (PMID: 37420267).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04074330||Phase Ib/II||Rituximab + Subasumstat||A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma||Completed||USA | ITA | GBR | FRA | ESP | DEU | CAN||2|